Magnesium and Migraine: Dosing, Forms, and What the Evidence Shows

Magnesium is the most extensively studied nutritional supplement in migraine prevention and one of the few for which there is a reasonable evidence base from randomized controlled trials. It is also among the most commonly recommended supplements by headache specialists for people with migraine, reflecting a convergence of biological plausibility, clinical evidence, and favorable safety profile. Understanding what the research actually shows about magnesium for migraine, which forms and doses have been studied, and how to use it appropriately gives people with migraine a foundation for an informed conversation with their healthcare provider.

The Biological Rationale

Magnesium is an essential mineral involved in more than three hundred enzymatic reactions in the body. Its relevance to migraine pathophysiology is particularly strong because of its role in neuronal excitability, vascular tone, and neurotransmitter function — all systems that are directly implicated in migraine.

Magnesium acts as a natural regulator of neuronal excitability by blocking N-methyl-D-aspartate glutamate receptors. Glutamatergic hyperexcitability is a feature of the migraine brain, and magnesium's role as an NMDA receptor antagonist provides a direct mechanism through which magnesium deficiency could lower the migraine threshold.

Magnesium also influences the production and release of serotonin, regulates the synthesis of nitric oxide, and affects the dilation and constriction of blood vessels. Each of these functions is relevant to migraine pathophysiology. Low magnesium levels have been documented in the serum, red blood cells, and cerebrospinal fluid of people with migraine during attacks, providing direct evidence of a connection between magnesium status and the migraine state.

What the Clinical Research Shows

Multiple randomized controlled trials have evaluated oral magnesium supplementation for migraine prevention. A landmark trial by Peikert and colleagues found that 600 milligrams per day of trimagnesium dicitrate significantly reduced migraine attack frequency compared to placebo over a twelve-week period. A subsequent trial by Pfaffenrath and colleagues found more modest results, possibly related to differences in patient selection and magnesium formulation.

A meta-analysis of randomized controlled trials concluded that oral magnesium supplementation was associated with significant reductions in migraine attack frequency compared to placebo, with the evidence being stronger for migraine with aura than for migraine without aura. The effect size in available trials is modest compared to the most effective pharmaceutical preventives, but the favorable safety profile and low cost make magnesium an appropriate consideration particularly as an adjunct to other management strategies.

Intravenous magnesium has a more established evidence base for acute migraine treatment, particularly in the emergency setting. Several randomized trials have found intravenous magnesium sulfate effective for aborting acute migraine attacks, with particularly strong evidence for its use in migraine with aura.

Forms of Magnesium and Their Absorption

Not all magnesium supplements are equivalent in their bioavailability or gastrointestinal tolerability. Magnesium oxide, the most commonly available and least expensive form, has relatively poor bioavailability and is more likely to cause gastrointestinal side effects including diarrhea.

More bioavailable forms include magnesium glycinate, which is well absorbed and well tolerated; magnesium malate, which has reasonable absorption; and magnesium citrate, which has moderate bioavailability and is more laxative than glycinate. Magnesium threonate is a newer formulation that may have superior penetration into the central nervous system but has limited migraine-specific clinical evidence.

Dosing Considerations

The doses used in migraine prevention trials have generally ranged from 400 to 600 milligrams of elemental magnesium per day, taken in divided doses with meals to reduce gastrointestinal side effects. The tolerable upper intake level for supplemental magnesium set by the National Institutes of Health is 350 milligrams per day for adults, above which gastrointestinal effects become more likely. Some clinical trials have used doses above this threshold under medical supervision.

Magnesium supplementation should be discussed with a healthcare provider, particularly for people with kidney disease, in whom magnesium clearance may be impaired.

Tracking Response to Magnesium

As with any preventive approach, assessing whether magnesium supplementation is contributing to migraine improvement requires systematic tracking. Maintaining a headache diary before starting supplementation and continuing it through the trial period provides the data needed to determine whether attack frequency, severity, or duration changes with treatment. A minimum trial period of two to three months is appropriate before drawing conclusions about effectiveness.